Clinical Trial Update: Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating combination of sitravatinib and tislelizumab in patients with advanced biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Sitravatinib (sitravatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Advanced Biliary Tract Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING